x

Like our Facebook Page

   
Early Times Newspaper Jammu, Leading Newspaper Jammu
 
Breaking News :   Artificial Intelligence & Agricultural Extension Education | No Place For Terror | Cong absent as CM Omar joins campaign trail | Mining mafia: Kupwara, Samba lead in illegal mineral extraction, transportation | DGP Prabhat reviews Kashmir security | ED raids premises of ex-minister, searched | CM approves Rs 19.99 crore ‘Used Water Management Project’ for Ganderbal | Illegal immigrants grab jobs, pose security threats: Amit Shah | Poonch Police seize Rs 8.5 lakh property | Daily wagers march to CM’s residence in Jammu | Sharma, Gupta take oath as newly elected members of Rajya Sabha | PM Modi to inaugurate commemoration event today | LG Sinha pays obeisance | IFS officer Sridhar transferred to J&K | Searches underway in Kishtwar | Gold prices climb | Firecrackers banned in Poonch | Back Issues  
 
news details
2-deoxy-D-glucose: DRDO's anti-COVID-19 drug is safe, will help patients recover faster, says INMAS scientist
5/12/2021 11:01:12 AM
Agencies
New Delhi: Dr Sudhir Chandna, Institute of Nuclear Medicine and Allied Sciences (INMAS) scientist has said the recently approved anti-COVID-19 drug 2-deoxy-D-glucose (2-DG) is completely safe and will help patients recover faster.

2-DG has been developed by INMAS, a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy`s Laboratories (DRL), Hyderabad.

"During clinical trials, it has yielded an effective result in curing patients infected with COVID-19. The medicine has gone through clinical trials on around 110 patients in the second phase. In the third phase, it was tried on 220 patients. It has shown better efficacy in phase two itself as compared to the standard care," Dr Chandna said.

"Recovery was two to three days faster for COVID-19 patients," he added.

He pointed out that in phase 3, the freedom from oxygen dependence has been seen in 42 per cent of the patients by the third day as compared to 31 per cent in standard care.

"This data has indicated that oxygen dependence reduced in a better way when we use this medicine along with standard care," Dr Chandna explained."The DRDO, along with its industry partner DRL, Hyderabad, started the clinical trials in April last year. The Phase 2 trials conducted from May to October 2020 on 110 patients. Based on successful results, DCGI further permitted the Phase 3 clinical trials. The Phase 3 clinical trial was conducted on 220 patients between December 2020 to March 2021," he added.

On being asked about the price, he said, "It will depend on the production and those factors are with Dr Reddy`s Laboratories who are our industry partners. As per our information and understanding, Dr. Reddy`s is trying that it comes out in a few days."
  Share This News with Your Friends on Social Network  
  Comment on this Story  
 
 
 
Early Times Android App
STOCK UPDATE
 
 
 
 
 
 
 
   
Home About Us Top Stories Local News National News Sports News Opinion Editorial ET Cetra Advertise with Us ET E-paper
 
 
J&K RELATED WEBSITES
J&K Govt. Official website
Jammu Kashmir Tourism
JKTDC
Mata Vaishnodevi Shrine Board
Shri Amarnath Ji Shrine Board
Shri Shiv Khori Shrine Board
UTILITY
Train Enquiry
IRCTC
Matavaishnodevi
BSNL
Jammu Kashmir Bank
State Bank of India
PUBLIC INTEREST
Passport Department
Income Tax Department
JK CAMPA
JK GAD
IT Education
Web Site Design Services
EDUCATION
Jammu University
Jammu University Results
JKBOSE
Kashmir University
IGNOU Jammu Center
SMVDU